All In Biotech

Drug Trial Radar · NCT03653702

Radiation-Free Technique for Evaluating Renal Scarring (RAFTERS)

Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Jul 1, 2027

Primary completion

Jun 2029

Study completion Jul 2029

Sponsor

Lead sponsor
Boston Children's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 31, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this research study the investigators want to study a safe, radiation-free technique known as contrast-enhanced ultrasound that may improve the ability to diagnose or evaluate renal scarring compared to regular ultrasound. This technique requires injection into a vein of a small amount of contrast material called Lumason. Contrast material is a type of dye that helps the investigators image the structures in the body more clearly. If this technique is successful, the need for DMSA studies may be avoided to diagnose or evaluate kidney scarring. DMSA is a more expensive test, causes radiation exposure, may require sedation and/or injection of contrast agents with the potential to cause allergic reactions.

Conditions

  • Vesico-Ureteral Reflux

Interventions

  • Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]Drug

    Lumason will be used as the contrast agent. Standard Lumason dose will be used: 0.03mL/kg up to a maximum dose of 2.4 milliliter (mL) per injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Performance of CEUS result and comparison to DMSATime frame: 3 months after final participant completes participation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Boston Children's Hospital

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.